Acute exacerbation of fibrosing interstitial lung disease; multicenter retrospective cohort study
Not Applicable
- Conditions
- Acute exacerbation of fibrosing interstitial lung disease
- Registration Number
- JPRN-UMIN000043025
- Lead Sponsor
- Wakayama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 384
Inclusion Criteria
Not provided
Exclusion Criteria
Cases in which the subject himself/herself has requested the refusal of the provision of information
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To clarify the clinical course of fibrosing interstitial lung disease.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie acute exacerbations in fibrosing interstitial lung disease as explored in JPRN-UMIN000043025?
How does the JPRN-UMIN000043025 cohort study compare outcomes of fibrosing interstitial lung disease exacerbations to standard-of-care management?
What biomarkers are associated with acute exacerbation risk in fibrosing interstitial lung disease patients from the Wakayama Medical University multicenter study?
Are there specific adverse events reported in JPRN-UMIN000043025 for fibrosing interstitial lung disease exacerbation treatment strategies?
What combination therapies or drug targets are being investigated alongside fibrosing interstitial lung disease exacerbation management in recent clinical research?